

# Quantity Limit

## Lidoderm, ZTLido

### Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name
Lidoderm	lidocaine patch 5%
ZTLido	lidocaine topical system

### Indications

#### FDA-approved Indications

##### Lidoderm

Lidoderm is indicated for relief of pain associated with post-herpetic neuralgia. It should be applied only to intact skin.

##### ZTLido

ZTLido (lidocaine topical system) 1.8% is indicated for relief of pain associated with post-herpetic neuralgia (PHN) in adults.

### Compendial Uses

Pain associated with diabetic neuropathy<sup>4</sup>

Pain associated with cancer-related neuropathy<sup>4,5</sup>

## Initial Limit Quantity

Limits should accumulate across all drugs and strengths up to highest quantity listed depending on the order the claims are processed.

The duration of 25 days is used for a 30-day fill period and 75 days is used for a 90-day fill period to allow time for refill processing.

Drug	1 Month Limit	3 Month Limit
Lidoderm 5% (lidocaine patch 5%)	90 patches / 25 days	270 patches / 75 days
ZTLido 1.8% (lidocaine topical system 1.8%)	90 patches / 25 days	270 patches / 75 days

## References

1. Lidoderm [package insert]. San Jose, CA: TPU Pharma, Inc.; December 2022.
2. ZTLido [package insert]. Palo Alto, CA: Scilex Pharmaceuticals Inc.; April 2021.
3. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Waltham, MA: UpToDate, Inc.; 2024. <https://online.lexi.com>. Accessed August 29, 2024.
4. Micromedex® (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: <https://www.micromedexsolutions.com/> (cited: 08/29/2024).
5. National Comprehensive Cancer Network (NCCN) Guidelines: Adult Cancer Pain V2.2023. National Comprehensive Cancer Network. Available from URL: [http://www.nccn.org/professionals/physician\\_gls/PDF/pain.pdf](http://www.nccn.org/professionals/physician_gls/PDF/pain.pdf). Accessed August 29, 2024.

## Document History

Written by: UM Development (SF)

Date Written: 06/2019

Revised: 09/2019 (no clinical changes); (CJM) 09/2020 (no clinical changes), (DFW) 09/2021 (added accumulation statement), (SS/TM) 09/2022 (no clinical changes), (TM) 09/2023 (no clinical changes); (VLS) 09/2024 (no clinical changes)

Reviewed: Medical Affairs (GAD) 06/2019, (CHART) 10/10/19; (CHART) 09/24/20, (CHART) 09/30/2021, 09/22/2022, 09/28/2023, 09/26/2024

External Review: 10/2019, 02/2020, 12/2020, 12/2021, 12/2022, 12/2023, 12/2024